Discover EVKEEZA® to help your HoFH patients reach their goals
The first and only ANGPTL3 inhibitor indicated as an adjunct to diet and other LDL-C lowering therapies for the treatment of adult and pediatric patients aged 5 years
and older with HoFH.
The effects of EVKEEZA on cardiovascular morbidity and mortality have not been determined.
Assistance in gaining access to EVKEEZA
UltraCare services are designed to help facilitate access to EVKEEZA treatment for patients with homozygous familial hypercholesterolemia (HoFH).
Enrolling in UltraCare may help your patients to:
- Understand their insurance coverage
- Access resources in the Patient Support Program (such as infusion services for EVKEEZA)
Download AN EVKEEZA Patient Enrolment Form
to start the enrolment process
Fill out the form with your patient and fax it to 1-833-592-2273 (CARE). Please note that a completed form is required for your enrolment.
For additional support, please call 1-833-388-5872 (U-LTRA).
LDL-C=low-density lipoprotein cholesterol; HoFH=homozygous familial hypercholesterolemia.
Indication and clinical use
EVKEEZA (evinacumab for injection) is indicated as an adjunct to diet and other low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of adult and pediatric patients aged 5 years and older with homozygous familial hypercholesterolemia (HoFH).
The effects of EVKEEZA on cardiovascular morbidity and mortality have not been determined.
Consult the Product Monograph at https://ultracaresupport.ca/assets/pdf/Canada_Evkeeza_Product_Monograph.pdf for contraindications, warnings, precautions, adverse reactions, interactions, dosing, and conditions of clinical use. The product monograph is also available by calling us at 1-833-388-5872.
Indication and clinical use
EVKEEZA (evinacumab for injection) is indicated as an adjunct to diet and other low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of adult and pediatric patients aged 5 years and older with homozygous familial hypercholesterolemia (HoFH).
Please consult the Product Monograph at https://ultracaresupport.ca/assets/pdf/Canada_Evkeeza_Product_Monograph.pdf for important information on warnings and precautions, the conditions of clinical use, adverse reactions, drug interactions and dosing instructions.
Consult the Product Monograph at https://ultracaresupport.ca/assets/pdf/Canada_Evkeeza_Product_Monograph.pdf for contraindications, warnings, precautions, adverse reactions, interactions, dosing, and conditions of clinical use. The product monograph is also available by calling us at 1-833-388-5872.
For additional information and to ask questions about medical information or medical affairs, please contact Ultragenyx Medical Affairs at 1-833-388-5872 (U-LTRA).
